drugset / Trial / NCT00060892

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

NCT00060892 ↗

Phase 2 Completed 104 enrolled AnGes USA, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study was to assess the overall safety of different dose regimens of AMG0001 (HGF transferred via plasmid vector) as well as evaluate the improvement of blood perfusion in subjects with critical limb ischemia (CLI). This study also evaluated the improvement in wound healing without adverse effects on the quality of life, as well as the potential reduction of amputation, mortality and rest pain in the CLI population.

Timeline

Start
2003-04
Primary completion
2006-05
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator AMG0001 Other / unclassified 0.4 mg Intramuscular
Comparator AMG0001 Other / unclassified 4 mg Intramuscular